Home › Metabolic Disorders › Florida › Orlando
Metabolic Disorders clinical trials in Orlando, FL
3 studies for Metabolic Disorders are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
RecruitingPhase 1
- Flourish Orlando, Orlando
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Winter Park · 5 mi away
- 89bio Clinical Study Site, Maitland · 6 mi away
- 89bio Clinical Study Site, Maitland · 6 mi away
- and 2 more
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Winter Park · 5 mi away
- 89bio Clinical Study Site, Ocoee · 10 mi away
- 89bio Clinical Study Site, Clermont · 24 mi away
About Metabolic Disorders
Your metabolism makes energy from the food you eat. A metabolic disorder disrupts this process. One example is diabetes. Learn more.
More about Metabolic Disorders on MedlinePlus
Metabolic Disorders trials in other cities
- Washington, DC11 studies
- Ann Arbor, MI8 studies
- New York City, NY7 studies
- St. Louis, MO7 studies
- Durham, NC7 studies
- Houston, TX6 studies
- Baltimore, MD6 studies
- Chicago, IL6 studies
- Boston, MA5 studies
- Los Angeles, CA4 studies
- Miami, FL4 studies
- Nashville, TN4 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Obesity31 studies
- Metastatic Cancer29 studies
- Overweight27 studies
- Alzheimer's Disease25 studies
- Type 2 Diabetes24 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Ovarian Cancer22 studies
- Ulcerative Colitis22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.